Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Median Overall Survival (mOS) generally ranges between 8-15 months, depending on primary site and stage

  80% confidence

• The dynamics of the NECs market are expected to change in the coming years due to the launch of emerging therapies

  80% confidence

• Platinum-based chemotherapy (cisplatin or carboplatin plus etoposide) remains an established global standard of care, producing relatively high objective response rates in newly diagnosed advanced NEC

  80% confidence

• The United States accounted for the largest neuroendocrine carcinoma treatment market size in 2025, compared to other major markets

  80% confidence

• The total neuroendocrine carcinoma treatment market size is expected to grow positively by 2036 in the leading markets

  80% confidence

• Novel therapeutic strategies beyond platinum chemotherapy are urgently needed for NEC and are being actively investigated in clinical trials, including immunotherapy combinations and molecularly targeted approaches that could eventually redefine standard care

  80% confidence

• The majority of NECs occur in the lung (31.1%), followed in decreasing frequency by stomach, pancreas, rectum, and esophagus

  80% confidence

• The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities

  80% confidence

• In the US, NECs represent only 10-20% of all NENs, which are highly proliferative tumors characterized by rapid disease progression

  80% confidence